Discontinued — last reported Q3 '19

Other

ROU Asset Obtained - Operating Lease

Vertex Pharmaceuticals ROU Asset Obtained - Operating Lease remained flat by 0.0% to $77.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 72.3%, from $280.23M to $77.75M. Over 2 years (FY 2023 to FY 2025), ROU Asset Obtained - Operating Lease shows an upward trend with a 1038.3% CAGR.

Analysis

StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2019
Last reportedQ3 2019

How to read this metric

Higher values indicate significant new investment in leased infrastructure, signaling growth or replacement of aging assets.

Detailed definition

This metric captures the non-cash increase in right-of-use (ROU) assets resulting from the initiation of new operating l...

Peer comparison

Disclosed as 'Right-of-use assets obtained in exchange for new operating lease liabilities' in the lease notes.

Metric ID: is_cvx_rou_asset_obtained_operating_lease

Historical Data

3 years
 FY'23FY'24FY'25
Value$2.40M$1.12B$311.00M
YoY Change—>999%-72.3%
Range$2.40M – $1.12B
CAGR>999%
Avg YoY Growth>999%
Median YoY Growth>999%

Frequently Asked Questions

What is Vertex Pharmaceuticals's rou asset obtained - operating lease?
Vertex Pharmaceuticals (VRTX) reported rou asset obtained - operating lease of $77.75M in Q4 2025.
How has Vertex Pharmaceuticals's rou asset obtained - operating lease changed year-over-year?
Vertex Pharmaceuticals's rou asset obtained - operating lease decreased by 72.3% year-over-year, from $280.23M to $77.75M.
What is the long-term trend for Vertex Pharmaceuticals's rou asset obtained - operating lease?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's rou asset obtained - operating lease has grown at a 1038.3% compound annual growth rate (CAGR), from $2.40M to $311.00M.
What does rou asset obtained - operating lease mean?
The value of new leased assets added to the balance sheet during the period.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.